In a move set to bolster Armstrong Teasdale’s intellectual property (IP) capabilities, Friedrich Laub has joined the firm as a partner in its New York office. Laub’s extensive experience encompasses a range of industries, including biopharmaceuticals, biotechnology, and molecular- and immuno-diagnostics. His role will focus on developing and implementing global IP and patent strategies, a critical aspect for companies in these rapidly evolving sectors.
The firm has expressed confidence in Laub’s ability to enhance their advisory services, particularly in IP transactional matters such as collaboration, licensing, and mergers and acquisitions. His appointment is perceived as a strategic fit to address the growing demands in the dynamic IP landscape.
Friedrich Laub’s expertise is anticipated to be invaluable for clients navigating the complexities of IP rights and strategies in these nuanced industries. The firm’s announcement about his addition underlines their commitment to strengthening their IP practice and providing comprehensive legal solutions to their clients.
For more details, you can view the original announcement on the Armstrong Teasdale website or access the coverage by Bloomberg Law here.